Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanobody CD5-CAR T Cell Therapy for R/R T-Cell Malignancies
NCT07070323Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nanobody CD5-chimeric antigen receptor T-cells in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (PTCL), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 30 days and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
nanobody CD5-chimeric antigen receptor T-cells
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07070323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070323.